UTHR - United Therapeutics Corporation
| Previous Close | 81.07 |
| Open | 80.83 |
| Bid | 78.25 x 3200 |
| Ask | 82.25 x 1800 |
| Day's Range | 77.78 - 80.84 |
| 52 Week Range | 77.78 - 130.00 |
| Volume | 683,255 |
| Avg. Volume | 691,100 |
| Market Cap | 3.427B |
| Beta (3Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire•11 days ago
United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , June 5, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond , Chief Financial Officer and Treasurer ...
- PR Newswire•19 days ago
United Therapeutics Corporation To Present at Jefferies 2019 Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , May 28, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond , Chief Financial Officer and Treasurer ...
- PR Newswire•last month
United Therapeutics And DEKA Announce FDA Clearance Of The Unity Subcutaneous Delivery System For Remodulin®
RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., May 7, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and DEKA Research & Development Corp. today announced receipt of 510(k) clearance by the U.S. Food and Drug Administration (FDA) for the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also referred to as the RemUnity™ system. The RemUnity system, which has been jointly developed by United Therapeutics and DEKA, is indicated for subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension, or PAH.
- PR Newswire•2 months ago
United Therapeutics Corporation Reports First Quarter 2019 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , May 1, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2019. ...
- PR Newswire•2 months ago
United Therapeutics Announces FDA Approval Of XPS™ And Steen Solution™ Used To Perform Centralized Ex-Vivo Lung Perfusion Services
SILVER SPRING, Md., April 29, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that its collaborator, XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (XVIVO.ST), has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the products XPS™ and STEEN Solution™. This approval means that STEEN Solution, XPS and the accompanying single-use articles are the only medical device products that are approved in the United States for ex-vivo lung perfusion (EVLP) of initially unacceptable donated lungs at body temperature.
- PR Newswire•2 months ago
United Therapeutics Corporation To Report First Quarter 2019 Financial Results Before The Market Opens On Wednesday, May 1, 2019
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2019 financial ...
- PR Newswire•2 months ago
United Therapeutics Issues Statement In Response To Meritless Lawsuit
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 17, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) was named as a defendant, along with Smiths Medical ASD, Inc., in a lawsuit filed in federal court by Sandoz Inc. and RareGen, LLC on April 16, 2019. The lawsuit alleges that United Therapeutics engaged in anticompetitive conduct in connection with plaintiffs' efforts to launch their generic version of Remodulin® (treprostinil) Injection. United Therapeutics was founded with the goal of serving patients with pulmonary arterial hypertension (PAH), and that remains our focus today.
- PR Newswire•2 months ago
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 8, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event. Accordingly, United Therapeutics has decided to discontinue further esuberaprost development.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Coeur Mining, Owens & Minor, Telenav, Cedar Realty Trust, j2 Global, and United Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•3 months ago
United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 12, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Oppenheimer 29th Annual Healthcare Conference in New York City. The presentation will take place on Tuesday, March 19, 2019, at 1:35 PM Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.
- PR Newswire•3 months ago
United Therapeutics Corporation To Present At Cowen And Company 39th Annual Health Care Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 4, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on Monday, March 11, 2019, at 4:10 PM Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.
- PR Newswire•4 months ago
United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 27, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ...
- PR Newswire•4 months ago
United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 20, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and annual 2018 ...
- PR Newswire•4 months ago
Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Jan. 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that key data from the FREEDOM-EV study of Orenitram® ...
- GlobeNewswire•5 months ago
Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•5 months ago
United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag
RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Upon closing, United Therapeutics paid Arena $800 million. As previously announced, the closing of the transactions contemplated by the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, among other conditions.
- PR Newswire•5 months ago
Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
SAN DIEGO, Jan. 24, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH). The global license agreement for ralinepag was announced on November 15, 2018. Ralinepag (APD811) is a next-generation, oral, selective potent, once-daily IP receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH).
- PR Newswire•5 months ago
United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation and the immediately following Q&A session will take place on Monday, January 7, 2019, at 2:30 PM Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.
- PR Newswire•6 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR
The investigation concerns whether United Therapeutics and certain of its officers and/or directors have breached fiduciary duties owed to the company and its investors. If you are a shareholder of United Therapeutics and are interested in obtaining additional information regarding this investigation, you are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation.
- PR Newswire•7 months ago
Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 29, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved Pr Unituxin (dinutuximab ...
- GlobeNewswire•7 months ago
Report: Exploring Fundamental Drivers Behind Harvard Bioscience, TTM Technologies, BSQUARE, United Therapeutics, KCAP Financial, and Gladstone Capital — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•7 months ago
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) and United Therapeutics Corporation (UTHR) today announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.
- PR Newswire•7 months ago
CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
CollPlant (CLGN) today announced the closing of a worldwide exclusive license, development and commercialization agreement with United Therapeutics Corporation (UTHR) for 3D bioprinted lung transplants. As previously announced, CollPlant granted United Therapeutics, through its wholly owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. CollPlant will manufacture and supply BioInk for a few years to meet development process demand, and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.
- CNW Group•7 months ago
Correvio Reports Third Quarter 2018 Financial Results
Correvio Reports Third Quarter 2018 Financial Results
- PR Newswire•7 months ago
Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors
Mesa has had a long and innovative career in environment, energy and sustainability at the city, state, national and global levels, and now writes and presents extensively on climate, energy, equity and urban systems relating to them. From 2012-2014, Mesa served as Director of the New York City Mayor's Office of Sustainability, where she led the pathbreaking OneNYC long term sustainability plan for the city.